![benzoapyrene phase 2 glutathione s transferase Benzo[a]pyrene (BaP) metabolites predominant in human plasma following escalating oral micro-dosing with [14C]-BaP Benzo(a)pyrene and cardiovascular diseases: An](https://ars.els-cdn.com/content/image/1-s2.0-S016041202100670X-ga1.jpg)
benzoapyrene phase 2 glutathione s transferase Benzo[a]pyrene (BaP) metabolites predominant in human plasma following escalating oral micro-dosing with [14C]-BaP Benzo(a)pyrene and cardiovascular diseases: An
Benzo(a)pyrene and cardiovascular diseases: An overview of pre clinical studies focused on the underlying molecular mechanism Frontiers benzo a pyrene phase 2 glutathione s transferase Benzo[a]pyrene induced nephrotoxicity driven by intricate Metabolic pathway of BaP benzo[a]pyrene (BaP), benzo[a]pyrene 7, Download Scientific Diagram A novel framework for polycyclic aromatic hydrocarbon doseeffect assessment: A case study of benzo[a]pyrene ScienceDirect ELECTROCHEMICAL DETECTION OF BENZO[A]PYRENE METABOLITE DNA DAMAGE : IMPLICATIONS OF NUCLEOBASE SEQUENCE AND ADDUCT STEREOCHEMISTRY Semantic Scholar Mitigation of benzo(a)pyrene induced hepatotoxicity and oxidative damage in Nile tilapia (Oreochromis niloticus) using N acetylcysteine loaded starch nanoparticles in porous alginate beads through the CYP1A Nrf2 HO 1 pathway Aquaculture International
Pay in 4 interest-free payments of $5.93 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
![benzoapyrene phase 2 glutathione s transferase Benzo[a]pyrene (BaP) metabolites predominant in human plasma following escalating oral micro-dosing with [14C]-BaP Benzo(a)pyrene and cardiovascular diseases: An](https://www.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/978475/fnut-09-978475-HTML/image_m/fnut-09-978475-g001.jpg)
![benzoapyrene phase 2 glutathione s transferase Benzo[a]pyrene (BaP) metabolites predominant in human plasma following escalating oral micro-dosing with [14C]-BaP Benzo(a)pyrene and cardiovascular diseases: An](https://www.frontiersin.org/files/Articles/1633648/xml-images/fmicb-16-1633648-g004.webp)
![benzoapyrene phase 2 glutathione s transferase Benzo[a]pyrene (BaP) metabolites predominant in human plasma following escalating oral micro-dosing with [14C]-BaP Benzo(a)pyrene and cardiovascular diseases: An](https://www.researchgate.net/publication/26332727/figure/fig3/AS:669332065513493@1536592608391/Metabolic-pathway-of-BaP-benzoapyrene-BaP-benzoapyrene-7.png)
![benzoapyrene phase 2 glutathione s transferase Benzo[a]pyrene (BaP) metabolites predominant in human plasma following escalating oral micro-dosing with [14C]-BaP Benzo(a)pyrene and cardiovascular diseases: An](https://ars.els-cdn.com/content/image/1-s2.0-S0160412026002035-ga1.jpg)
![benzoapyrene phase 2 glutathione s transferase Benzo[a]pyrene (BaP) metabolites predominant in human plasma following escalating oral micro-dosing with [14C]-BaP Benzo(a)pyrene and cardiovascular diseases: An](https://figures.semanticscholar.org/454ead816b5c1b5f4eb19d05a5d6244a04649098/20-Figure1.2-1.png)
![benzoapyrene phase 2 glutathione s transferase Benzo[a]pyrene (BaP) metabolites predominant in human plasma following escalating oral micro-dosing with [14C]-BaP Benzo(a)pyrene and cardiovascular diseases: An](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs10499-025-01884-2/MediaObjects/10499_2025_1884_Fig1_HTML.png)